SSY GROUP (02005.HK): Propylthiouracil Tablets and Calcium Gluconate and Sodium Chloride Injection Obtain Drug Registration Approvals, Deemed to Have Passed Consistency Evaluation
NewTimeSpace News: SSY GROUP (02005.HK) announced on 10 July that Propylthiouracil Tablets (50mg) and Calcium Gluconate and Sodium Chloride Injection have secured drug registration approvals issued by NMPA, both deemed to have passed consistency evaluation. Propylthiouracil Tablets are the third domestically approved product of this kind, indicated for hyperthyroidism. The injection is used for acute hypocalcaemia, magnesium poisoning and fluoride poisoning.
NewTimeSpace News: On 10 July 2026, SSY GROUP (02005.HK) released a voluntary announcement. The Group has obtained the drug production registration approval for Propylthiouracil Tablets (50mg). Classified as Category 4 chemical drug, the product is deemed to have passed consistency evaluation, making the Group the third domestic enterprise to receive approval. The medicine is mainly used for various types of hyperthyroidism in patients intolerant to methimazole.
Meanwhile, the Group obtained registration approval for Calcium Gluconate and Sodium Chloride Injection (50ml:1g/0.3375g). As a Category 3 chemical drug, it is also deemed to have passed consistency evaluation. It is indicated for the treatment of acute hypocalcaemia, magnesium poisoning and fluoride poisoning. Together with other approved specifications under the Group, it enriches the calcium preparation portfolio.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- SSY GROUP (02005.HK): 95 Varieties Included in National Essential Medicines List (2026 Edition)
- SSY Group (02005.HK): Trustee Acquires 1 Million Shares Under Restricted Share Incentive Scheme
- SSY GROUP(02005.HK): Trustee Purchases 2 Million Shares Under Restricted Share Award Scheme at Average Price of HK$2.1585
- SSY GROUP(02005.HK): NMPA Grants Manufacturing Approval for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution
- SSY Group(02005.HK): Trustee Purchases 380,000 Shares on Open Market Under Restricted Share Award Scheme at Average Price of HK$2.2124
